<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276834</url>
  </required_header>
  <id_info>
    <org_study_id>NOCTX-2</org_study_id>
    <secondary_id>2009-011605-16</secondary_id>
    <nct_id>NCT01276834</nct_id>
  </id_info>
  <brief_title>Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation</brief_title>
  <acronym>NOCTX-2</acronym>
  <official_title>Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dianet Dialysis Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dianet Dialysis Centers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare in a prospective randomised way the effect of two different immunosuppressive
      regimens - mTOR-based regimen or CNI-based regimen - on the progression of coronary artery
      calcification in renal transplant patients measured at baseline, 1, 2, and 3 years after
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient patients enrolled
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in coronary artery calcification score</measure>
    <time_frame>3 years</time_frame>
    <description>Comparison in a randomised way the effect of a calcineurin-based immunosuppressive regimen with an mTOR-based regimen on progression of coronary calcification on renal transplant patients.
The results of this study will provide more insight in protection against cardiovascular disease in renal transplant patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>everolimus-based immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immunosuppression with everolimus, prednisone and mycophenolate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard immunosuppression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immunosuppression with tacrolimus, prednisone and mycophenolate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>comparison of everolimus-based and CNI-based immunosuppression</description>
    <arm_group_label>everolimus-based immunosuppression</arm_group_label>
    <arm_group_label>standard immunosuppression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-75 yr

          -  Willingness to provide written informed consent

          -  Ability to understand the study procedures

        Exclusion Criteria:

          -  Life expectancy &lt; 3 months

          -  Claustrophobia

          -  Allergy to iodinated contrast

          -  Treatment incompliance

          -  Pregnancy

          -  Highly HLA-sensitized patients

          -  Severe dyslipidemia or proteinuria

          -  Severe leucopenia or thrombocytopenia

          -  GFR &lt; 30 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franka E van Reekum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dianet Dialysis Centers</investigator_affiliation>
    <investigator_full_name>B.C. van Jaarsveld, MD PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

